English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

From Research to Clinical Application Multi-Parameter Testing: Marker Panels for the Early Detection of Complex Diseases Multi Parameter Analysis can open novel diagnostic opportunities for the early diagnosis and screening of multimodal diseases like cancer. Single proteins have so far failed to describe such complex diseases. Being able to screen with a set of analytes is one promising way to overcome the present limitations. Various marker identification tools including proteomics approaches have been successfully applied to identify new screening markers for early detection of colorectal cancer (CRC). CRC is one of the most incident cancers worldwide and early detection is clearly a key factor in reducing mortality from CRC. Several screening methods are recommended, including colonoscopy, fecal occult blood testing (FOBT) and fecal DNA analysis. Of these annual stool testing with the guaiac based FOBT is most often applied, in spite of limitations such as low sensitivity and dietary influences. Though proce dures with improved performance eg. immunolo gical FOBT are available, a screening assay for CRC in serum that could easily be integrated in any health check-up would be highly welcome. A positive result of such a test would trigger a follow-up colonoscopy for an exact diagnosis. In this review we will cover aspects of marker identification strategies and describe a well structured marker validation process that is based on clinically characterized sample materials. Finally the value of analytical multi-parameter platforms enabling the combination of multi markers in routine diagnostics settings is outlined. An appropriate multi-parameter immunochemistry platform concept, currently developed under the working name »IMPACT« will be introduced. Od Istraživanja do Kliničke Primene: Paneli Markera za Ranu Detekciju Složenih Bolesti Analiza više parametara (multi-parameter analysis) može doneti nove dijagnostičke mogućnosti za ranu dijagnozu i testiranje multimodalnih bolesti poput raka. Pojedinačni proteini dosad nisu uspeli da opišu tako složene bolesti. Mogućnost testiranja pomoću seta analita najavljuje prevazilaženje postojećih ograničenja. Različite alatke za identifikaciju markera uključujući proteomske pristupe uspešno se primenjuju za identifikaciju novih markera za rano otkrivanje kolorektalnog kancera. Kolorektalni kancer je jedan od najčešćih kancera u celom svetu a rana detekcija je ključni faktor za smanjenje mortaliteta od te vrste raka. Preporučeno je nekoliko metoda za testiranje, uključujući kolonoskopiju, analizu okultnog krvarenja u stolici i analizu DNK u stolici. Najčešće se primenjuje godišnje testiranje stolice metodom gvajak zasnovano na analizi okultnog krvarenja u stolici, uprkos ograničenjima kao što su niska senzitivnost i uticaj ishrane. Mada postoje postupci s poboljšanim performansama, npr. imunološko testiranje okultnog krvarenja u stolici, skrining test na kolorektalni rak koji bi se lako integrisao u svaki zdravstveni pregled bio bi veoma korisan. Pozitivan rezultat takvog testa ukazao bi na potrebu za kolonoskopijom radi precizne dijagnoze. U ovom radu biće razmotreni aspekti strategija za identifikaciju markera i opisan valjano struktuiran postupak validacije markera zasnovan na klinički okarakterisanim uzorcima materijala. Najzad, biće naznačena vrednost analitičkih platformi s više parametara koje omogućuju kombinovanje multimarkera u rutinskoj dijagnostici. Biće predstavljen i koncept odgovarajuće imunohemijske platforme s više parametara koja se trenutno razvija pod radnim nazivom »IMPACT«.